Skip to main content
TipRanks
Go Ultimate75% OFF

Jason Scott Slakter Insider Profile

4 Followers

Jason Scott Slakter, former CEO, Director at NeuBase Therapeutics, holds 1.56M shares in NeuBase Therapeutics (Ticker: NBSE). Most recently, Jason Scott Slakter Bought 142,858 shares of NeuBase Therapeutics on Apr 13, 2017 for an estimated value of $100.00K.

Jason Scott Slakter's Trading History

NBSE
NeuBase Therapeutics
Apr 13, 2017―Informative Buy100.00K$591.05K
NBSE
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Apr 13, 2017Informative Buy$100.00K142,858$0.70-70.60%
Aug 02, 2016Uninformative Buy$0.00497,859$0.00―
Jun 21, 2016Informative Buy$25.00K8,786$2.84-76.10%
May 26, 2016Informative Buy$11.45K3,682$3.10-79.80%
May 25, 2016Informative Buy$88.38K28,068$3.14-80.60%

You May Also Like

Jason Scott Slakter insider profile FAQ

What is the percentage of profitable transactions made by Jason Scott Slakter?
The percentage of profitable transactions made by Jason Scott Slakter is 0%.
What is the average return per transaction made by Jason Scott Slakter?
The average return per transaction made by Jason Scott Slakter is -66.40%.
What stocks does Jason Scott Slakter hold?
Jason Scott Slakter holds: NBSE stocks.
What was Jason Scott Slakter’s latest transaction?
Jason Scott Slakter’s latest transaction was an Informative Buy of $100.00K.
What was Jason Scott Slakter's most profitable transaction?
Jason Scott Slakter’s most profitable transaction was an Informative Buy of NBSE stock on November 4, 2015. The return on the trade was -12.60%.
What is Jason Scott Slakter's role in NeuBase Therapeutics?
Jason Scott Slakter's role in NeuBase Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.